Posaconazole Tablet Formulation at 400 Milligrams Daily Achieves Desired Minimum Serum Concentrations in Adult Patients with a Hematologic Malignancy or Stem Cell Transplant | Zendy

Aaron N. Pham | Zendy; Joseph Bubalo | Zendy; James S. Lewis | Zendy

Open Access

Posaconazole Tablet Formulation at 400 Milligrams Daily Achieves Desired Minimum Serum Concentrations in Adult Patients with a Hematologic Malignancy or Stem Cell Transplant

Author(s) -

Aaron N. Pham,

Joseph Bubalo,

James S. Lewis

Publication year - 2016

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01489-16

Subject(s) - posaconazole , hematologic malignancy , hematologic neoplasms , medicine , stem cell , pharmacokinetics , malignancy , pharmacology , maximum tolerated dose , transplantation , gastroenterology , voriconazole , antifungal , biology , dermatology , genetics

We describe our experience using the posaconazole 400-mg delayed-release tablet formulation once daily in 20 patients with hematologic malignancy or hematopoietic stem cell transplant who were unable to attain prespecified target minimum serum (trough) concentrations for treatment or prophylaxis of invasive fungal infection. The higher dose allowed the majority of patients to achieve prespecified target trough concentrations without incurring additional toxicities.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research